Purple Biotech (XTAE:PPBT) Minority Interest : ₪0.35 Mil (As of Dec. 2023)

View and export this data going back to 1978. Start your Free Trial

What is Purple Biotech Minority Interest?

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Purple Biotech's minority interest for the quarter that ended in Dec. 2023 was ₪0.35 Mil.

Purple Biotech Minority Interest Historical Data

The historical data trend for Purple Biotech's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Purple Biotech Minority Interest Chart

Purple Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Minority Interest

Get a 7-Day Free Trial

1.68

1.39

1.07

0.72

0.35

Purple Biotech Quarterly Data
	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Minority Interest	Get a 7-Day Free Trial															0.72	0.62	0.54	0.46	0.35

Purple Biotech Minority Interest Calculation

Purple Biotech (XTAE:PPBT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Purple Biotech Ltd (XTAE:PPBT) » Definitions » Minority Interest

Comparable Companies

Traded in Other Exchanges

PPBT:USA 1YI1:Germany

Address

4 Oppenheimer Street, Science Park, Rehovot, ISR, 7670104

Website

https://www.purple-biotech.com

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24.